Create a free QxMD account to take advantage of the features offered by Read like saving your papers and creating collections.

Get Started

JOURNAL ARTICLE

REVIEW

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

(no author information available yet)

Journal of Hepatology 2018, 69 (1): 182-236

No abstract text is available yet for this article.

Full Text Links

Find Full Text Links for this Article

You are not logged in. Sign Up or Log In to join the discussion.

Sort by: Most Recent • Highest Rated

Brrnrhbrrrrrbrřh6brhnhnrrrrrnhnrnrrr4 hnrnr3g3

Posted 8 Nov, 2019 at 8:56

Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. Ahsun Riaz, Khairuddin Memon, Frank H Miller, Paul Nikolaidis, Laura M Kulik, Robert J Lewandowski, Robert K Ryu, Kent T Sato, Vanessa L Gates, Mary F Mulcahy, Talia Baker, Ed Wang, Ramona Gupta, Ritu Nayar, Al B Benson, Michael Abecassis, Reed Omary, Riad Salem Journal of Hepatology 2011, 54 (4): 695-704

EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation. Huzi Li, Zhi Guo, Tongguo Si, Haitao Wang European Journal of Gastroenterology & Hepatology 2013, 25 (5): 620-7

Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. Ahsun Riaz, Frank H Miller, Laura M Kulik, Paul Nikolaidis, Vahid Yaghmai, Robert J Lewandowski, Mary F Mulcahy, Robert K Ryu, Kent T Sato, Ramona Gupta, Ed Wang, Talia Baker, Michael Abecassis, Al B Benson, Albert A Nemcek, Reed Omary, Riad Salem JAMA: the Journal of the American Medical Association 2010 March 17, 303 (11): 1062-9

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (no author information available yet) Journal of Hepatology 2012, 56 (4): 908-43

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (no author information available yet) European Journal of Cancer 2012, 48 (5): 599-641

Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. Khairuddin Memon, Laura Kulik, Robert J Lewandowski, Edward Wang, Robert K Ryu, Ahsun Riaz, Paul Nikolaidis, Frank H Miller, Vahid Yaghmai, Talia Baker, Michael Abecassis, Al B Benson, Mary F Mulcahy, Reed A Omary, Riad Salem Journal of Hepatology 2012, 56 (5): 1112-20

EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma. Lei Liu, Weijuan Wang, Hui Chen, Yan Zhao, Wei Bai, Zhanxin Yin, Chuangye He, Jia Jia, Man Yang, Jielai Xia, Daiming Fan, Guohong Han Clinical Cancer Research 2014 March 15, 20 (6): 1623-31

EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral? Emilie Blond, Emmanuel Disse, Charlotte Cuerq, Jocelyne Drai, Pierre-Jean Valette, Martine Laville, Charles Thivolet, Chantal Simon, Cyrielle Caussy Diabetologia 2017, 60 (7): 1218-1222

Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. Chai Hong Rim, Jinsil Seong Radiation Oncology Journal 2016, 34 (3): 160-167

Make the most of Read.
Download the mobile app.

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Read